Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
107 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Acinetobacter Infections - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Acinetobacter Infections - Pipeline Review, H2 2014', provides an overview of the Acinetobacter Infections's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Acinetobacter Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acinetobacter Infections and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Acinetobacter Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Acinetobacter Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Acinetobacter Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Acinetobacter Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acinetobacter Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acinetobacter Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Acinetobacter Infections Overview 10 Therapeutics Development 11 Pipeline Products for Acinetobacter Infections - Overview 11 Pipeline Products for Acinetobacter Infections - Comparative Analysis 12 Acinetobacter Infections - Therapeutics under Development by Companies 13 Acinetobacter Infections - Therapeutics under Investigation by Universities/Institutes 16 Acinetobacter Infections - Pipeline Products Glance 17 Clinical Stage Products 17 Early Stage Products 18 Acinetobacter Infections - Products under Development by Companies 19 Acinetobacter Infections - Products under Investigation by Universities/Institutes 21 Acinetobacter Infections - Companies Involved in Therapeutics Development 22 Achaogen Inc. 22 Adenium Biotech ApS 23 AmpliPhi Biosciences Corporation 24 Aridis Pharmaceuticals LLC 25 AstraZeneca PLC 26 ConjuGon, Inc. 27 Evolva SA 28 FOB Synthesis, Inc. 29 LegoChem Biosciences, Inc 30 Melinta Therapeutics, Inc 31 Northern Antibiotics Oy 32 Nosopharm SAS 33 Novan, Inc. 34 Omnia Molecular Ltd. 35 Pfizer Inc. 36 Sarepta Therapeutics, Inc. 37 Sealife PHARMA GMBH 38 Shionogi & Co., Ltd. 39 Synthetic Biologics, Inc. 40 Trana Discovery, Inc. 41 Vaxdyn, S.L. 42 Acinetobacter Infections - Therapeutics Assessment 43 Assessment by Monotherapy Products 43 Assessment by Combination Products 44 Assessment by Target 45 Assessment by Mechanism of Action 47 Assessment by Route of Administration 49 Assessment by Molecule Type 51 Drug Profiles 53 A-3APO - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 AA-139 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Antibiotics to Inhibit tRNA For Hospital-Acquired Gram-Negative Bacterial Infections - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Antisense Oligonucleotide for Acinetobacter baumannii Infections - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 AR-401 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 Biologics for Acinetobacter Baumanii - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 BXN-112 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 Cephalosporin + Beta-Lactamase Inhibitor - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 EV-035 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 FSI-1671 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 FSI-1686 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 GN-4474 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 LCB-100200 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 MDN-0057 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 MDN-0058 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 MDN-0059 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 MDN-0060 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 NAB-7061 - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 NAB-739 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 NAB-741 - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 NOSO-95 - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 NVN-4428 - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 RX-04 - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 RX-05 - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 RXP-873 - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 S-649266 - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 SB-204 - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 SLP-0905 - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 Small Molecule for Acinetobacter baumannii Infections - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 Small Molecule for Gram-Negative Nosocomial Infections - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 Small Molecules for Gram Negative Bacterial Infections - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 Small Molecules for Gram-Negative Bacterial Infections - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 Small Molecules to Inhibit NDH-1 for Acinetobacter baumannii Infections - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 Small Molecules to Inhibit Tryptophanyl-tRNA synthetase for Bacterial Infections - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 SYN-001 - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 VXD-001 - Drug Profile 98 Product Description 98 Mechanism of Action 98 R&D Progress 98 VXD-003 - Drug Profile 99 Product Description 99 Mechanism of Action 99 R&D Progress 99 Acinetobacter Infections - Recent Pipeline Updates 100 Acinetobacter Infections - Dormant Projects 105 Appendix 106 Methodology 106 Coverage 106 Secondary Research 106 Primary Research 106 Expert Panel Validation 106 Contact Us 107 Disclaimer 107
List of Tables Number of Products under Development for Acinetobacter Infections, H2 2014 11 Number of Products under Development for Acinetobacter Infections - Comparative Analysis, H2 2014 12 Number of Products under Development by Companies, H2 2014 14 Number of Products under Development by Companies, H2 2014 (Contd..1) 15 Number of Products under Investigation by Universities/Institutes, H2 2014 16 Comparative Analysis by Clinical Stage Development, H2 2014 17 Comparative Analysis by Early Stage Development, H2 2014 18 Products under Development by Companies, H2 2014 19 Products under Development by Companies, H2 2014 (Contd..1) 20 Products under Investigation by Universities/Institutes, H2 2014 21 Acinetobacter Infections - Pipeline by Achaogen Inc., H2 2014 22 Acinetobacter Infections - Pipeline by Adenium Biotech ApS, H2 2014 23 Acinetobacter Infections - Pipeline by AmpliPhi Biosciences Corporation, H2 2014 24 Acinetobacter Infections - Pipeline by Aridis Pharmaceuticals LLC, H2 2014 25 Acinetobacter Infections - Pipeline by AstraZeneca PLC, H2 2014 26 Acinetobacter Infections - Pipeline by ConjuGon, Inc., H2 2014 27 Acinetobacter Infections - Pipeline by Evolva SA, H2 2014 28 Acinetobacter Infections - Pipeline by FOB Synthesis, Inc., H2 2014 29 Acinetobacter Infections - Pipeline by LegoChem Biosciences, Inc, H2 2014 30 Acinetobacter Infections - Pipeline by Melinta Therapeutics, Inc, H2 2014 31 Acinetobacter Infections - Pipeline by Northern Antibiotics Oy, H2 2014 32 Acinetobacter Infections - Pipeline by Nosopharm SAS, H2 2014 33 Acinetobacter Infections - Pipeline by Novan, Inc., H2 2014 34 Acinetobacter Infections - Pipeline by Omnia Molecular Ltd., H2 2014 35 Acinetobacter Infections - Pipeline by Pfizer Inc., H2 2014 36 Acinetobacter Infections - Pipeline by Sarepta Therapeutics, Inc., H2 2014 37 Acinetobacter Infections - Pipeline by Sealife PHARMA GMBH, H2 2014 38 Acinetobacter Infections - Pipeline by Shionogi & Co., Ltd., H2 2014 39 Acinetobacter Infections - Pipeline by Synthetic Biologics, Inc., H2 2014 40 Acinetobacter Infections - Pipeline by Trana Discovery, Inc., H2 2014 41 Acinetobacter Infections - Pipeline by Vaxdyn, S.L., H2 2014 42 Assessment by Monotherapy Products, H2 2014 43 Assessment by Combination Products, H2 2014 44 Number of Products by Stage and Target, H2 2014 46 Number of Products by Stage and Mechanism of Action, H2 2014 48 Number of Products by Stage and Route of Administration, H2 2014 50 Number of Products by Stage and Molecule Type, H2 2014 52 Acinetobacter Infections Therapeutics - Recent Pipeline Updates, H2 2014 100 Acinetobacter Infections - Dormant Projects, H2 2014 105
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.